Prospective Study
Copyright ©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1326-1340
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1326
Table 3 Subclinical proximal tubulopathy prevalence at month 24 in the entecavir, naive and tenofovir disoproxil groups
Global (n = 138); n (%); (95%CI)ETV (n = 28); n (%); (95%CI)Naive (n = 84); n (%); (95%CI)TDF (n = 26); n (%); (95%CI)P value; ETV vs naiveP value; TDF vs naive
Missing values4592214
SPT prevalence at M24; (n = 93)29 (31.2%); (22.0-41.6)4 (21.1%); (6.1-45.6)19 (30.7%); (19.6-43.7)6 (50.00%); (21.1-78.9)0.4210.322
1Chi2 test.
2Fisher’s exact test. CI: Confidence interval; ETV: Entecavir; SPT: Subclinical proximal tubulopathy; TDF: Tenofovir disoproxil.
  • Citation: Brayette A, Essig M, Carrier P, Debette-Gratien M, Labrunie A, Alain S, Maynard M, Ganne-Carrié N, Nguyen-Khac E, Pinet P, De Ledinghen V, Renou C, Mathurin P, Vanlemmens C, Di Martino V, Gervais A, Foucher J, Isabelle FH, Vergniol J, Hourmand-Ollivier I, Cohen D, Duval X, Poynard T, Bardou M, Abergel A, Dao MT, Thévenot T, Hiriart JB, Canva V, Lassailly G, Aurières C, Boyer N, Thabut D, Bernard PH, Schnee M, Larrey D, Hanslik B, Hommel S, Jacques J, Loustaud-Ratti V. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. World J Hepatol 2020; 12(12): 1326-1340
  • URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1326.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1326